Brepocitinib

Brepocitinib
Clinical data
Trade namesLisraya
Other namesPF-06700841
AHFS/Drugs.comLisraya
License data
Routes of
administration		By mouth
Drug classAnti-inflammatory
ATC code
  • None
Legal status
Legal status
Identifiers
  • ((1S)-2,2-difluorocyclopropyl)[(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC18H21F2N7O
Molar mass389.411 g·mol−1
3D model (JSmol)
  • Cn1cc(cn1)Nc2nccc(n2)N3C[C@@H]4CC[C@H](C3)N4C(=O)[C@@H]5CC5(F)F
  • InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1
  • Key:BUWBRTXGQRBBHG-MJBXVCDLSA-N

Brepocitinib, sold under the brand name Lisraya, is a medication used for the treatment of dermatomyositis. It is a Janus kinase and tyrosine kinase 2 inhibitor. It is taken by mouth.

The most common adverse reactions include upper respiratory tract infection, headache, fatigue, urinary tract infection, and nausea.

Brepocitinib was approved for medical use in the United States in August 2026.

Medical uses

Brepocitinib is indicated for the treatment of dermatomyositis in adults.

Dermatomyositis is a rare autoimmune disease in which the immune system attacks the muscles and skin, causing chronic inflammation, progressive muscle weakness, and distinctive skin rashes.

History

The efficacy and safety of brepocitinib were evaluated in a phase III randomized, double-blind, multi-center, placebo-controlled study (NCT05437263) that included 241 adults with dermatomyositis. Participants were randomized to receive brepocitinib 30 mg once daily, brepocitinib 15 mg once daily or placebo for a 52-week treatment period.

Society and culture

Brepocitinib was approved for medical use in the United States in August 2026. The US Food and Drug Administration (FDA) granted the application for brepocitinib orphan drug and priority review designations. The FDA granted the approval of Lisraya to Priovant Therapeutics.

Names

Brepocitinib is the international nonproprietary name.

Brepocitinib is sold under the brand name Lisraya.

References

  1. 1 2 3 4 5 https://priovant.com/wp-content/uploads/2026/08/LISRAYA_USPI_Aug2026.pdf
  2. 1 2 3 4 5 6 7 "FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults". U.S. Food and Drug Administration (FDA). 27 August 2026. Retrieved 31 August 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  3. 1 2 "Roivant Announces FDA Approval of Lisraya (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S." (Press release). Roivant Sciences. 27 August 2026. Retrieved 31 August 2026.
  4. ↑ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.

Further reading